The research on the immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine, M.RCAg-1 formulation with different adjuvants

Chinese Journal of Microbiology and Immunology (China)

Volumn 31, Issue 12, 2011, Pages 1117-1123

  Wang, Jian ^a   Lin, Yahui ^b   Sun, Cheng Jin ^a   Li, Li Li ^a   Chen, Xiang Peng ^a   Li, Jun ^a   Wang, Heng ^b   Zhang, Zhen Long ^a  

^a NATIONAL VACCINE AND SERUM INSTITUTE   (China)

^b NONE

Author keywords

Adjuvant; M. RCAg 1; Malaria vaccine

Indexed keywords

CHIMERIC PROTEIN; CYTOKINE; EPITOPE; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MONTANIDE ISA 51; MONTANIDE ISA 720; PARASITE ANTIGEN; RCAG 1 CHIMERIC PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BIOSENSOR; CELLULAR IMMUNITY; CONCENTRATION (PARAMETERS); CYTOKINE PRODUCTION; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ESCHERICHIA COLI; FEMALE; GROWTH INHIBITION; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 84864395858     PISSN: 02545101     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0254-5101.2011.12.015     Document Type: Article

References (15)

1. Yang T, Wang H N, Wang X, et al. Multivalent DNA vaccine enhanced protection efficacy against infectious bronchitis virus in chickens. J Vet Med Sci, 2009, 71(12): 1585-1590.
2. Takala S L, Plowe C V. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol, 2009, 31(9): 560-573.
3. Mahanty S, Saul A, Miller L H. Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J Exp Biol, 2003, 206(Pt 21): 3781-3788.
4. Cai Q L, Wei F, Lin Y H, et al. Immunogenicity of polyepitope libraries assembled by epitope shuffling: an approach to the development of chimeric gene vaccination against malaria. Vaccine, 2004, 23(2): 267-277.
5. Cai Q, Peng G, Bu L, et al. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling. Vaccine, 2007, 25(28): 5155-5165.
6. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol, 2007, 5(7): 505-517.
7. Good M F. Towards a blood-stage vaccine for malaria: are we following all the leads? Nat Rev Immunol, 2001, 1(2): 117-125.
8. Good M F, Doolan D L. Immune effector mechanisms in malaria. Curr Opin Immunol, 1999, 11(4): 412-419.
9. Audibert F M, Lise L D. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today, 1993, 14(6): 281-284.
10. Brewer J M, Conacher M, Satoskar A, et al. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol, 1996, 26(9): 2062-2066.
11. Kenter G G, Welters M J, Valentijn A R, et al. Phase I immuno-therapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res, 2008, 14(1): 169-177.
12. Hu J, Chen Z, Gu J, et al. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults. PLoS One, 2008, 3(4): e1952.
13. Osorio M, Gracia E, Rodríguez E, et al. Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. Cancer Biol Ther, 2008, 7(4): 488-495.
14. Davies G. Vaccine adjuvant formulation: a relatively neglected field that is crucial to vaccine success. Expert Rev Vaccines, 2008, 7(3): 287-291.
15. Moreno R, Pöltl-Frank F, Stüber D, et al. Rhoptry-associated protein 1-binding monoclonal antibody raised against a heterologous peptide sequence inhibits Plasmodium falciparum growth in vitro. Infect Immun, 2001, 69(4): 2558-2568.